Literature DB >> 16554356

Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.

K Michaelis1, M M Hoffmann, S Dreis, E Herbert, R N Alyautdin, M Michaelis, J Kreuter, K Langer.   

Abstract

Drug delivery to the brain is becoming more and more important but is severely restricted by the blood-brain barrier. Nanoparticles coated with polysorbates have previously been shown to enable the transport of several drugs across the blood-brain barrier, which under normal circumstances is impermeable to these compounds. Apolipoprotein E was suggested to mediate this drug transport across the blood-brain barrier. In the present study, apolipoprotein E was coupled by chemical methods to nanoparticles made of human serum albumin (HSA-NP). Loperamide, which does not cross the blood-brain barrier but exerts antinociceptive effects after direct injection into the brain, was used as model drug. Apolipoprotein E was chemically bound via linkers to loperamide-loaded HSA-NP. This preparation induced antinociceptive effects in the tail-flick test in ICR mice after i.v. injection. In contrast, nanoparticles linked to apolipoprotein E variants that do not recognize lipoprotein receptors failed to induce these effects. These results indicate that apolipoprotein E attached to the surface of nanoparticles facilitates transport of drugs across the blood-brain barrier, probably after interaction with lipoprotein receptors on the brain capillary endothelial cell membranes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554356     DOI: 10.1124/jpet.105.097139

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  61 in total

Review 1.  In vivo methods to study uptake of nanoparticles into the brain.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Wim E Hennink; Gert Storm; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-10-07       Impact factor: 4.200

Review 2.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

Review 3.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 4.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

5.  Future prospects of nanoparticles on brain targeted drug delivery.

Authors:  C Chakraborty; B Sarkar; C H Hsu; Z H Wen; C S Lin; P C Shieh
Journal:  J Neurooncol       Date:  2008-12-02       Impact factor: 4.130

Review 6.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

Review 7.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

Review 8.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

Review 9.  Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.

Authors:  Sean M Geary; Aliasger K Salem
Journal:  Crit Rev Oncog       Date:  2014

10.  Nanoparticulate transport of oximes over an in vitro blood-brain barrier model.

Authors:  Sylvia Wagner; Jürgen Kufleitner; Anja Zensi; Miriam Dadparvar; Sascha Wien; Judith Bungert; Tikva Vogel; Franz Worek; Jörg Kreuter; Hagen von Briesen
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.